Wikipedia -WSS

Wikipedia

author：fashion 2025-10-02 22:15:20 - browse：55

Alnylam headquarters — Kristoffer Tripplaar/Sipa USA/AP

A group of advisers to the Food and Drug Administration voted in favor of Alnylam Pharmaceuticals’ treatment for a debilitating heart disease Wednesday, but only after a day-long debate challenging whether the drug’s modest observed effects were actually meaningful for patients.

The group of independent experts voted 9-3 that the benefits of Alnylam’s drug, called patisiran, outweighed its risks for patients with ATTR-CM, a progressive disease that leads to fatal heart failure if left untreated. The FDA, which is not required to follow the advice of advisers, is expected to make a final decision on patisiran by Oct. 8.

“It’s like a light wind blowing in favor of patisiran over placebo,” said David Cella, a neurologist at the Northwestern University Feinberg School of Medicine who voted in favor of patisiran. David Moliterno, a cardiologist at the University of Kentucky, added that “the good news in this story is that while there may be a small benefit, it doesn’t look like there’s a signal for harm.”

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： In Memoriam: Notable people who died in 2023
Next article： Obesity now affects over 1 billion people worldwide, study finds

WSS

Change Healthcare cyberattack outage could last weeks

Senators start work on Medicare physician payment reform

Obesity now affects over 1 billion people worldwide, study finds

Biden report: The neurospychology of memory and aging

How digital tools helped lower hypertension in marginalized patients

A Q&A with Aletha Maybank, AMA’s chief health equity officer

knowledge

Wikipedia

knowledge

Affirmative action in medical school literally saved lives

What we’ve learned from the Aduhelm mess

Food as medicine: CMS rules hamper 'prescribing' of fruits, veggies

RaDonda Vaught to speak at CommonSpirit event on patient safety

State Dept. review finds Biden bears some blame for Afghanistan failures

Readout LOUD podcast: How biotech is using artificial intelligence

Cancer drug shortages should be causing more outrage

KalVista pill reduced swelling 'attacks' caused by genetic disease

New Eli Lilly Alzheimer’s data poses Medicare coverage conundrum

Kale crackers and hibiscus tea: My five days on a 'fasting diet'

leisure time

Robert F. Kennedy is pitching centrism on health, even on abortion

BioAge raises $170M for combination therapy with Zepbound

Why did Pfizer dish out millions for a Super Bowl ad?

Gilead might be held responsible for not developing a drug

A Q&A with Aletha Maybank, AMA’s chief health equity officer

Biogen Alzheimer’s drug launch off to slow start

hotspot

focus

hotspot

hotspot